{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rioci 1?<\/h3>\n

Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for pulmonale arteri\u00eble hypertensie (PAH)<\/strong>. PAH is een specifieke, progressieve en zeldzame aandoening \u2014 niet hetzelfde als systemische hypertensie<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n

What Is Rioci 1?<\/h2>\n

Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n

Pulmonale arteri\u00eble hypertensie (PAH) is geen systemische hypertensie.<\/strong> PAH verwijst specifiek naar verhoogde druk in de pulmonale arteri\u00eble circulatie (\u226520 mmHg gemiddelde pulmonale arteri\u00eble druk met pulmonale vasculaire weerstand \u22652 Wood Units volgens de 2022 ESC\/ERS richtlijnen). Het is zeldzaam (geschat 15-50 per miljoen volwassenen), progressief en zonder behandeling heeft het een slechte prognose (historische 5-jaarsoverleving \u223c30%). Moderne PAH-gerichte therapie heeft de 5-jaarsoverleving verbeterd tot 60-70% in expertcentra.<\/p>\n

Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n

How Riociguat Works<\/h2>\n

Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n

Bewijs<\/h2>\n

PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n

Dosering en Monitoring<\/h2>\n

Dosering:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n

Monitoring:<\/strong> bij aanvang en vervolgens elke 3-6 maanden \u2014 WHO-functionele klasse, 6-minuten looptest, NT-proBNP, herhalingsechocardiografie, en (op langere intervallen) rechterhartkatheterisatie. Alles uitgevoerd via een gespecialiseerd PAH-centrum.<\/p>\n

BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n

Bijwerkingen<\/h2>\n